Efficacy of a paclitaxel eluting stent compared to bare nitinol stents to treat symptomatic femoropopliteal lesions: principal outcomes of the randomized EMINENT trial

For many experts nitinol bare stents (BMS) remain the routine treatment for femoropopliteal lesions (FP). The aim of the EMINENT study was to compare the efficacy of the Eluvia® paclitaxel eluting stent (DES) (Boston Scientific, Marlborough, MA, USA) and of BMS for the treatment of FP lesions.